Patient Home
Welcome to Health Vidya. Discover trusted care and your own health — all in one place.
These highlights do not include all the information needed to use WEZLANA safely and effectively. See full prescribing information for WEZLANA. WEZLANA™ (ustekinumab-auub) injection, for subcutaneous or intravenous use Initial U.S. Approval: 2023WEZLANA™ (ustekinumab-auub) is biosimilarBiosimilar means that the biological product is approved based on data demonstrating that it is highly similar to an FDA-approved biological product known as a reference product, and that there are no clinically meaningful differences between the biosimilar product and the reference product. Biosimilarity of WEZLANA has been demonstrated for the condition(s) of use (e.g., indication(s), dosing regimen(s), strength(s), dosage form(s), and route(s) of administration described in its Full Prescribing Information. to STELARA® (ustekinumab).
Medication labelWhy this: Advisory · dailymed-prescription
WEZLANA is indicated for the treatment of adults and pediatric patients 6 years of age and older with moderate to severe plaque psoriasis who are candidates for phototherapy or systemic therapy. WEZLANA is indicated for the treatment of adults and pediatric patients 6 years of age and older with active psoriatic arthritis. WEZLANA is indicated for the treatment of adult patients with moderately to severely active Crohn's disease. WEZLANA is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis.
- generic_name
- ustekinumab-auub
- product_names
- ustekinumab-auub
- ndc
- 84612-076, 84612-076-01, 84612-089, 84612-089-01, 84612-055, 84612-055-01, 84612-066, 84612-066-01, 84612-876, 84612-876-01, 84612-889, 84612-889-01, 84612-855, 84612-855-01
- group
- drugs
- license
- us-gov-pd
- attribution
- Courtesy of the National Library of Medicine
- reviewed
- 2026-09-18
- language
- en